Business Operations

Johnson & Johnson will spend more than $55 billion on manufacturing, research and technology in the U.S. over the next four years, the biopharmaceutical company announced (Axios). These investments include a long-planned $2 billion state-of-the-art biologics facility in Wilson, North Carolina.

What’s going on: The NAM joined J&J for the groundbreaking of the 500,000-square-foot biologics manufacturing plant in Wilson on Friday.

• The White House praised the announcement and J&J’s commitment to manufacturing in America. North Carolina Gov. Josh Stein and Rep. Don Davis (D-NC) also attended the ceremony to highlight the facility’s importance to the state economy and the jobs it will bring to the state.

Other projects across the total investment will include:

• Three new advanced manufacturing sites and the expansion of several facilities in J&J’s Innovative Medicine and MedTech businesses;
• Significant spending on research-and-development infrastructure “aimed at developing lifesaving and life-changing treatments in areas such as oncology, neuroscience, immunology, cardiovascular disease and robotic surgery,” according to the company; and
• More investment aimed at speeding drug discovery and development, supporting workforce training and improving business operations.

Common goal: The Wilson site demonstrates the power of collaboration, Johnson & Johnson Executive Vice President and Chief Technical Operations & Risk Officer and NAM Board Chair Kathy Wengel said at the groundbreaking.

• “Today is a tangible example of how J&J is bringing communities, government, education and industry together to achieve the common goal of creating a future-ready workforce that is ready to tackle the toughest health challenges and achieve new breakthroughs.”

Why it’s important: The investments will strengthen not only North Carolina’s economy, but the U.S. economy as a whole, NAM President and CEO Jay Timmons said at the event.

• “Every $1 invested in manufacturing adds more than $2.60 to the economy. That’s top-of-the-line ROI for communities, neighborhoods and cities like Wilson—among the best ROIs you can get. And every new manufacturing job supports, on average, five additional jobs in other industries.”

The big picture: The new Wilson facility will generate a $3 billion impact across North Carolina in its first decade of operation.

• It will support about 5,000 jobs during construction and create more than 500 permanent positions—paying an average of $109,000 a year—in the state (WRAL News).

Certainty and predictability: These investments illustrate why policymakers must ensure that manufacturers have more certainty and predictability, not less, Timmons added.

• “Manufacturing—especially biopharmaceutical manufacturing—requires years of planning, ingenuity and investment decisions,” he said. “When there’s stability, common sense and competitive policies, companies like Johnson & Johnson can plan for the future—and plan big.”
• Timmons said that to “make more wins like this happen,” elected officials must stay focused on a comprehensive manufacturing strategy, including a “competitive tax policy, balanced regulations, prompt permitting, abundant energy and smart trade policies.”

The tax factor: J&J credits the 2017 Tax Cuts and Jobs Act with allowing it to increase its investment, according to MassDevice.

• Investments like J&J’s “are why it is critical that pro-growth provisions of the 2017 tax law be made permanent and more competitive,” Timmons wrote in a social post. “If Congress fails to act, 6 million American jobs—184,000 in North Carolina—will be wiped out. We can’t let that happen.”
• But if Congress does preserve the measures, manufacturing will win, Timmons said. “And when manufacturing wins, America wins.”